#4-14E. Dual Target Strategy: Combining Ixekizumab and Tirzepatide for Psoriatic Arthritis and Obesity (ArthritisRheumatol, 2026)

Are you struggling to achieve optimal disease control in psoriatic arthritis (PsA) patients who are concurrently battling overweight or obesity? The phase 3b TOGETHER-PsA trial enrolled 271 adults with active PsA and overweight or obesity to compare the concomitant use of ixekizumab and tirzepatide against ixekizumab monotherapy. At 36 weeks, the combination therapy demonstrated a significantly higher rate of simultaneous achievement of an ACR50 response and a minimum 10% weight reduction compared to monotherapy (31.7% versus 0.8%), alongside profound improvements in joint symptoms, physical function, and quality of life. The most pivotal clinical takeaway is that dually targeting immune and metabolic pathways with an IL-17 inhibitor and a GIP/GLP-1 receptor agonist offers synergistic benefits for both articular manifestations and metabolic parameters. However, when critically appraising this study, clinicians must consider its open-label design, which potentially introduces evaluation bias—especially in subjective patient-reported outcomes—and note that the trial was conducted exclusively in the United States. For practicing physicians, this highlights the necessity of a comprehensive treatment paradigm that actively addresses weight management as a modifiable factor to optimize overall disease control.

Citation: Merola JF, Genovese MC, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70134

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.